article thumbnail

PhRMA seeks to revive Medicare price negotiations lawsuit, blasts Biden's request for IRA expansion

Fierce Pharma

As President Joe Biden doubles down on the price negotiation meas | As President Joe Biden doubles down on the price negotiation measures in the Inflation Reduction Act, prominent industry lobbying group the Pharmaceutical Research and Manufacturers of America isn’t letting its legal challenge go down without a fight.

article thumbnail

And so pharma profiteers again

World of DTC Marketing

This comes at a time when industry fart sniffing publications like Fierce Pharma report “pharma continues to shine under the pandemic spotlight. Pharma earned a solid No. Thus vaccine research was relatively neglected until last year – when COVID-19 suddenly became a rich country issue, and state funding poured in.

Pharma 191
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

PhRMA joins legal battle over Inflation Reduction Act's 'price-setting' measures

Fierce Pharma

After Merck and Bristol Myers Squibb took shots at the Inflation Reduction Act (IRA) in separate lawsuits, influential trade group Pharmaceutical Research and Manufacturers of America (PhRMA)—plus | Trade group PhRMA is the latest to go after the IRA in a lawsuit claiming violations of the Fifth and Eighth amendments.

article thumbnail

After Pfizer's exit, UCB splits from industry trade group BIO

Fierce Pharma

UCB will still retain its membership in other top trade groups, including the Pharmaceutical Research and Manufacturers Association of America (PhRMA). . | Both companies opted not to renew their 2024 memberships with the Biotechnology Innovation Organization (BIO).

article thumbnail

Pharma, patient advocates clash over Inflation Reduction Act

Pharmaceutical Technology

At a lively panel at Financial Times US Pharma and Biotech Summit on May 16, panellists were at odds over whether the new legislation would improve treatment affordability or stifle pharma innovation. Meanwhile, the pharma industry is contending with a tough economic climate and a series of inflationary and supply chain pressures.

article thumbnail

Despite ban, Martin Shkreli can’t seem to kick the pharma habit

pharmaphorum

” That is certainly a departure from Shkreli’s earlier efforts to disrupt the healthcare category by inflating the price of critical HIV medication Daraprim by around 5,000% when he was chief executive at Turing Pharma. .”

Pharma 52
article thumbnail

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

PharmaKinnex

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve! The pharmaceutical industry of 2022 is very different from the space that we all knew in 2012, 2016, or even 2020. What are these new and existing pharma regulations, expectations, and challenges? COVID-19, Telemedicine, & The New Pharma Landscape.

Pharma 52